#1 Clinical Trials Search in Europe

Lacnotuzumab

Lacnotuzumab, also known as MCS110, is an investigational drug being studied in clinical trials for the treatment of various types of advanced cancer. This article provides an overview of the ongoing research, focusing on its safety, tolerability, and potential benefits for patients with advanced malignancies.

Table of Contents

What is Lacnotuzumab?

Lacnotuzumab, also known as MCS110, is an investigational drug being developed by Novartis Pharma AG for the treatment of advanced cancer[1]. It is a type of medication called a monoclonal antibody, which is a laboratory-made protein that mimics the immune system’s ability to fight off harmful cells in the body[1].

How Does Lacnotuzumab Work?

Lacnotuzumab is a recombinant human monoclonal antibody of the IgG1 kappa class. It works by targeting a specific protein in the body called human macrophage colony-stimulating factor[1]. This protein plays a role in the growth and survival of certain types of cancer cells. By blocking this protein, lacnotuzumab may help slow down or stop the growth of cancer cells.

What Conditions Does Lacnotuzumab Treat?

Lacnotuzumab is being studied for the treatment of different types of advanced cancer[1]. Advanced cancer refers to cancer that has spread from where it started to other parts of the body. This type of cancer is often more difficult to treat, which is why new medications like lacnotuzumab are being developed and tested.

Clinical Trials and Research

Lacnotuzumab is currently being studied in clinical trials. These trials are taking place in several European countries, including Belgium, France, Poland, Hungary, and the Czech Republic[1]. The purpose of these trials is to evaluate the safety and effectiveness of lacnotuzumab in patients with advanced cancer.

One particular study is described as an “open-label, multi-center rollover protocol.” This means that:

  • Open-label: Both the researchers and participants know which treatment is being used.
  • Multi-center: The study is being conducted at multiple hospitals or research centers.
  • Rollover protocol: It allows patients who have participated in previous studies of lacnotuzumab to continue receiving the treatment if they are benefiting from it[1].

Administration and Dosage

Lacnotuzumab is administered as a concentrate for solution for infusion. This means it is given directly into the bloodstream through a vein (intravenously)[1]. The maximum daily dose being studied is 7.5 mg/kg (milligrams per kilogram of body weight)[1]. However, it’s important to note that the optimal dosage is still being determined through clinical trials.

Potential Benefits and Safety

The main objective of the current clinical trials is to collect data on the safety and tolerability of lacnotuzumab, both when used alone and in combination with other cancer treatments[1]. Researchers are particularly interested in:

  • The frequency and nature of side effects (adverse events)
  • How many patients need to have their dose interrupted or reduced
  • How long patients are able to continue treatment

It’s important to remember that lacnotuzumab is still an experimental treatment. While it shows promise, more research is needed to fully understand its benefits and risks. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name Lacnotuzumab (MCS110)
Drug Type Recombinant human monoclonal antibody
Target Human macrophage colony-stimulating factor
Condition Studied Different types of advanced cancer
Administration Intravenous infusion
Maximum Daily Dose 7.5 mg/kg
Maximum Total Dose 1330 mg/kg
Maximum Treatment Period 533 days
Primary Objective Collect safety and tolerability data
Secondary Objective Provide continued access to study treatment

FAQ

  • What is Lacnotuzumab? Lacnotuzumab, also known as MCS110, is a recombinant human monoclonal antibody that targets human macrophage colony-stimulating factor. It is being studied as a potential treatment for various types of advanced cancer.
  • How is Lacnotuzumab administered? Lacnotuzumab is administered intravenously (through a vein) as a concentrate for solution for infusion. The dosage is calculated based on the patient's weight, with a maximum daily dose of 7.5 mg/kg.
  • What is the main goal of the clinical trial involving Lacnotuzumab? The main objective of the clinical trial is to collect safety and tolerability data for Lacnotuzumab, either as a single agent or in combination with other study treatments for patients with advanced cancer.
  • Who is eligible to participate in this clinical trial? Eligible participants are those who are currently enrolled in a pre-defined Novartis-sponsored study and are receiving Lacnotuzumab, either alone or in combination with other treatments. They must be deriving clinical benefit from the treatment and have demonstrated compliance with the parent protocol requirements.
  • What are the primary endpoints of the study? The primary endpoints of the study are the frequency and nature of adverse events (AEs) and serious adverse events (SAEs), as well as the number of subjects requiring dose interruptions or reductions during treatment with Lacnotuzumab.

Ongoing Clinical Trials on Lacnotuzumab

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

Glossary

  • Lacnotuzumab: A recombinant human monoclonal antibody that targets human macrophage colony-stimulating factor, being studied as a potential treatment for advanced cancer.
  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. They can be used to detect or treat cancer.
  • Intravenous use: A method of administering medication directly into a vein using a needle or tube.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Serious adverse event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization, causes a significant incapacity, or requires intervention to prevent permanent impairment.
  • Dose interruption: A temporary stop in the administration of a medication, usually due to side effects or other medical reasons.
  • Dose reduction: Lowering the amount of medication given to a patient, often to manage side effects while maintaining therapeutic benefit.
  • Clinical benefit: A positive effect that a treatment has on a patient's disease or condition, such as improved symptoms or extended survival.
  • Parent protocol: The original study plan or set of instructions that guides the conduct of a clinical trial.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-spartalizumab-for-patients-with-advanced-cancer/